A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
ClinicalTrials.gov processed this data on October 30, 2024. Link to the current ClinicalTrials.gov record.Recruitment Status
COMPLETED - HAS RESULTS(See Contacts and Locations)
Verified October 2024 by Iterum Therapeutics, International Limited
Sponsor
Iterum Therapeutics, International LimitedInformation Provided by (Responsible Party)
Iterum Therapeutics, International LimitedClinicaltrials.gov Identifier
NCT05584657Other Study ID Numbers: IT001-310
First Submitted: October 14, 2022
First Posted: October 18, 2022
Results First Posted: November 20, 2024
Last Update Posted: November 20, 2024
Last Verified: October 2024
History of Changes
Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.
Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.
Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.
For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.
See also the Web Policies and Notices for the NIH web site.
Study Description
IT001-310 is a Phase 3, randomized, multicenter, double-blind, double dummy, controlled study to compare oral sulopenem etzadroxil/probenecid (oral sulopenem) to oral amoxicillin/clavulanate for the treatment of adult female patients with uncomplicated urinary tract infection. Approximately 1966 adult women with uncomplicated urinary tract infection will be randomized in a 1:1 fashion to receive either oral sulopenem etzadroxil/probenecid or oral amoxicillin/clavulanate twice daily for 5 days. The primary outcome measure for efficacy evaluation will be the overall success (combined clinical and microbiologic success) on Day 12 (± 1 day)/Test of Cure (TOC).Condition or Disease | Intervention/Treatment |
---|---|
|
|
Study Design
Study Type | Interventional |
---|---|
Actual Enrollment | 2229 participants |
Design Allocation | Randomized |
Interventional Model | Parallel Assignment |
Masking | Quadruple |
Primary Purpose | Treatment |
Official Title | A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women |
Study Start Date | October 18, 2022 |
Actual Primary Completion Date | November 3, 2023 |
Actual Study Completion Date | November 21, 2023 |
Groups and Cohorts
Group/ Cohort | Intervention/ Treatment |
---|---|
|
|
|
|
Outcome Measures
Primary Outcome Measures
- Overall Success [Day 12+/-1 day] Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen)
- Overall Success Susceptible Population [Day 12+/-1 day] Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen)
Secondary Outcome Measures
- Clinical Success Modified Intent-to-treat Population [Day 12+/-1 day] Resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms
- Clinical Success [Day 12+/-1 day] Resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms
- Clinical Success Susceptible Population [Day 12+/-1 day] Resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms
- Microbiologic Success [Day 12+/-1 day] Eradication of the Baseline Pathogen
- Microbiologic Success Susceptible Population [Day 12+/-1 day] Microbiologic Success: Eradication of the Baseline Pathogen
Eligibility Criteria
Ages Eligible for Study | 18 Years and Older (Adult, Older Adult) |
---|---|
Sexes Eligible for Study | Female |
Accepts Healthy Volunteers | No |
Inclusion Criteria |
|
Exclusion Criteria |
|
Contacts and Locations
Sponsors and Collaborators | Iterum Therapeutics, International Limited |
---|---|
Locations |
|
Investigators |
Study Documents (Full Text)
- Documents Provided by Iterum Therapeutics, International Limited: Study Protocol December 5, 2022
- Documents Provided by Iterum Therapeutics, International Limited: Statistical Analysis Plan January 10, 2024
More Information
Additional Relevant MeSH Terms
- Infections
- Communicable Diseases
- Urinary Tract Infections
- Cystitis
- Disease Attributes
- Pathologic Processes
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Diseases